Targeted Solicitations

NCI issues targeted grant solicitations with specific focus areas. The receipt dates for these opportunities may or may not align with the Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) standard receipt dates (i.e., January 5, April 5, and September 5), so please read the solicitation carefully before applying.

 

Current Solicitations

• Notice of Special Interest (NOSI): National Cancer Institute SBIR/STTR Program Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (NOT-CA-21-062) NCI encourages grant applications from small businesses to develop or adapt, apply, and validate existing or emerging technologies into user-friendly, low-resource setting-appropriate technologies for cancer prevention, diagnosis, or treatment.

• SBIR Technology Transfer (NOT-NS-22-017) (R43/R44 Clinical Trial Not Allowed) This targeted funding opportunity aims to help move commercially-viable technologies from the NIH Intramural Program to the marketplace.

• Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers (NOT-CA-23-004) The goal of the funding opportunity is to facilitate early cancer biomarker assay development, verification, qualification, and validation utilizing statistically powered retrospective cohorts and/or through prospective studies in the appropriate populations with a sound study design.